EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to research and develop T cell receptor (TCR)-mediated T cell engager therapy (TCR-TCE) for the treatment of immune-related diseases, including solid tumors.
Partnership Details
The partnership integrates the expertise of both companies across multiple targets. Medigene brings its capabilities in generating and characterizing TCRs with the 3S principles of Sensitivity, Specificity, and Safety. EpimAb contributes its proprietary CD3 antibody and T-FIT (TCR Fab Tandem) platform. The resulting bispecific therapy is designed to deliver highly specific immune responses while minimizing off-target effects, aiming to improve patient outcomes.
Joint Development Commitment
Both parties are committed to jointly developing and equally owning the TCR-TCE constructs. This collaboration combines their respective strengths in TCR-related research and development, with the goal of creating effective therapies for immune-related diseases. The partnership is expected to accelerate the development of innovative treatment options in the field of immuno-oncology.-Fineline Info & Tech
Leave a Reply